The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.
The aims of this study were to assess the efficacy and safety of rituximab in patients with active rheumatoid arthritis (RA). The authors surveyed randomized controlled trials (RCTs) that examined the efficacy of rituximab in disease modifying anti-rheumatic drug (DMARD) (including methotrexate [MTX]) or tumor necrosis factor (TNF)-blocker-resistant or intolerant patients with active RA using Medline, the Cochrane Controlled Trials Register, and manual searches. Meta-analysis of RCTs was performed to determine the treatment efficacy and safety outcomes of rituximab (1 course, consisting of two infusions of 1,000 mg each) concomitant with MTX. The three RCTs included 938 DMARD or TNF-blocker-resistant or intolerant RA patients. Follow-up periods ranged from 24 to 48 weeks. American College of Rheumatology response (ACR) 20, ACR50, and ACR70 response rates were significantly higher for the rituximab plus MTX than for placebo controls (primary efficacy outcome, ACR50; risk ratio [RR] 3.648, 95% confidence interval [CI] 2.478-5.369, P < 0.001). For those treated with rituximab, the incidence adverse events of all systems were not higher than in those treated with placebo (RR 1.062, 95% CI 0.912-1.236, P = 0.438). With respect to the number of patients that experienced at least one serious adverse event, no significant difference was observed between patients treated with rituximab and placebo (RR 0.855, 95% CI 0.622-1.174, P = 0.333). A single course of rituximab with concomitant MTX therapy was found to be effective in DMARD or TNF-blocker-resistant or intolerant patients with active RA.
Lee
Young Ho
YH
Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Anam-dong 5-ga, Seongbuk-gu, Seoul 136-705, Korea. lyhcgh@korea.ac.kr
Bae
Sang-Cheol
SC
Song
Gwan Gyu
GG
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D016206:Databases, Bibliographic; D004351:Drug Resistance / Q000187:drug effects; D004359:Drug Therapy, Combination; D006304:Health Status; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020127:Recovery of Function; D012042:Registries; D000069283:Rituximab; D016896:Treatment Outcome
D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab; D008727:Methotrexate
Arthritis Rheum. 1995 Jun;38(6):727-35
7779114
Joint Bone Spine. 2008 Oct;75(5):526-32
18571968
Arthritis Rheum. 2008 Jun 15;59(6):785-93
18512710
Control Clin Trials. 1996 Feb;17(1):1-12
8721797
Lancet. 1997 Oct 18;350(9085):1182
9343537
Blood. 1994 Jan 15;83(2):435-45
7506951
BMJ. 1997 Sep 13;315(7109):629-34
9310563
Curr Dir Autoimmun. 2005;8:175-92
15564721
Curr Opin Rheumatol. 2003 May;15(3):246-52
12707577
Ann Rheum Dis. 2008 Nov;67(11):1648-9
18854518
Stat Med. 2002 Jun 15;21(11):1539-58
12111919
Nat Med. 2000 Apr;6(4):443-6
10742152
J Rheumatol. 2008 Jan;35(1):20-30
18050385
N Engl J Med. 1990 May 3;322(18):1277-89
2271017
Ann Intern Med. 2002 Jun 18;136(12):908-22
12069565
Arthritis Rheum. 1988 Mar;31(3):315-24
3358796
Ann Intern Med. 2001 Apr 17;134(8):695-706
11304108
N Engl J Med. 2004 Jun 17;350(25):2572-81
15201414
Arthritis Rheum. 2006 Sep;54(9):2793-806
16947627
Ann Rheum Dis. 2009 Feb;68(2):216-21
18388156
Arthritis Rheum. 2006 May;54(5):1390-400
16649186
Rheumatology (Oxford). 2001 Feb;40(2):205-11
11257159
J Clin Oncol. 1998 Aug;16(8):2825-33
9704735
Rheumatology (Oxford). 2006 Dec;45(12):1505-13
17062648
J Clin Pharmacol. 2007 Sep;47(9):1119-28
17766699